中新藥業(600329.SH):津滬深醫藥要約收購實施完畢 5月6日復牌
格隆匯4月30日丨中新藥業(600329.SH)公佈,公司於2021年3月29日公吿了《天津中新藥業集團股份有限公司要約收購報吿書》,津滬深生物醫藥科技有限公司(以下簡稱“津滬深醫藥”或“收購人”)向除天津市醫藥集團有限公司(以下簡稱“天藥集團”)所持股份以外的中新藥業全部無限售條件流通A股股份發出全面收購要約,要約收購期限為2021年3月31日至2021年4月29日。
目前,本次全面要約收購已經實施完畢,在要約收購期限內,預受要約户數3個,共計4,497股股份接受津滬深醫藥發出的要約,佔公司總股本的0.00058%。公司股票將於2021年5月6日開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.